Meyer Handelman Co. lowered its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 29.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 288,372 shares of the biopharmaceutical company’s stock after selling 120,412 shares during the quarter. Meyer Handelman Co.’s holdings in Gilead Sciences were worth $20,659,000 as of its most recent SEC filing.
Other institutional investors have also recently modified their holdings of the company. Letko Brosseau & Associates Inc. lifted its position in shares of Gilead Sciences by 0.8% during the 2nd quarter. Letko Brosseau & Associates Inc. now owns 1,391,826 shares of the biopharmaceutical company’s stock worth $98,513,000 after buying an additional 10,477 shares during the last quarter. BlackRock Inc. lifted its position in shares of Gilead Sciences by 1.9% during the 2nd quarter. BlackRock Inc. now owns 104,906,494 shares of the biopharmaceutical company’s stock worth $7,425,281,000 after buying an additional 1,937,031 shares during the last quarter. Amalgamated Bank lifted its position in shares of Gilead Sciences by 51.2% during the 2nd quarter. Amalgamated Bank now owns 151,787 shares of the biopharmaceutical company’s stock worth $10,743,000 after buying an additional 51,430 shares during the last quarter. BlueMountain Capital Management LLC lifted its position in shares of Gilead Sciences by 1,807.5% during the 2nd quarter. BlueMountain Capital Management LLC now owns 111,968 shares of the biopharmaceutical company’s stock worth $7,925,000 after buying an additional 106,098 shares during the last quarter. Finally, BT Investment Management Ltd purchased a new stake in shares of Gilead Sciences during the 2nd quarter worth approximately $22,070,000. Institutional investors own 77.83% of the company’s stock.
Several brokerages have recently weighed in on GILD. Barclays restated an “overweight” rating and set a $95.00 price objective (up previously from $90.00) on shares of Gilead Sciences in a research report on Tuesday, March 6th. BidaskClub downgraded shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research report on Saturday, March 3rd. Zacks Investment Research upgraded shares of Gilead Sciences from a “sell” rating to a “hold” rating in a research report on Wednesday, February 28th. Royal Bank of Canada restated a “buy” rating and set a $94.00 price objective on shares of Gilead Sciences in a research report on Friday, February 23rd. Finally, Leerink Swann restated a “market perform” rating and set a $80.00 price objective (down previously from $83.00) on shares of Gilead Sciences in a research report on Thursday, February 22nd. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $88.61.
In other Gilead Sciences news, CFO Robin L. Washington sold 5,000 shares of the business’s stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $80.31, for a total value of $401,550.00. Following the transaction, the chief financial officer now directly owns 23,749 shares of the company’s stock, valued at approximately $1,907,282.19. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider John C. Martin sold 50,000 shares of the business’s stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $73.62, for a total transaction of $3,681,000.00. Following the completion of the transaction, the insider now directly owns 3,046,766 shares in the company, valued at $224,302,912.92. The disclosure for this sale can be found here. Insiders sold a total of 436,101 shares of company stock worth $34,541,560 over the last three months. 1.30% of the stock is currently owned by corporate insiders.
Gilead Sciences, Inc. (GILD) opened at $75.57 on Friday. The company has a debt-to-equity ratio of 1.53, a current ratio of 2.74 and a quick ratio of 2.67. The stock has a market cap of $100,199.45, a price-to-earnings ratio of 8.96, a price-to-earnings-growth ratio of -1.76 and a beta of 1.24. Gilead Sciences, Inc. has a 12 month low of $63.76 and a 12 month high of $89.54.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.67 by $0.11. The company had revenue of $5.95 billion for the quarter, compared to analysts’ expectations of $5.71 billion. Gilead Sciences had a net margin of 17.73% and a return on equity of 50.29%. Gilead Sciences’s revenue was down 18.7% compared to the same quarter last year. During the same period in the previous year, the company posted $2.70 EPS. equities research analysts anticipate that Gilead Sciences, Inc. will post 6.21 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 29th. Shareholders of record on Friday, March 16th will be paid a $0.57 dividend. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.52. This represents a $2.28 annualized dividend and a yield of 3.02%. The ex-dividend date is Thursday, March 15th. Gilead Sciences’s payout ratio is currently 65.52%.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.